Functional mushrooms are making a strong comeback in wellness discussions, and three names clearly dominate recent research: reishi, cordyceps, and lion's mane. Between promises regarding fatigue, cognition, and immunity, it's easy to get lost in the marketing. The most useful approach, therefore, remains to examine what the most recent human clinical trials are saying, separating the interesting signals from the truly solid conclusions.
Good news: there is now more data available than a few years ago. Less good news: the quality of evidence remains uneven, depending on the mushroom and the desired effect. In short, some results are promising, but they don't yet justify turning these ingredients into miracle cures. Here's a clear, practical, and up-to-date overview of new clinical trials concerning reishi, cordyceps, and lion's mane.
Why are new clinical trials of medicinal mushrooms attracting so much attention?
The growing interest in adaptogenic and functional mushrooms stems from a twofold trend. On the one hand, more and more adults are seeking natural solutions to support energy, concentration, or the body's defenses. On the other hand, clinical research is finally beginning to produce more structured human trials, allowing us to move beyond anecdotal evidence.
But it's crucial to remember one key point: not all results are created equal. A randomized, double-blind, placebo-controlled trial doesn't carry the same weight as a routine survey or a pilot study with a small number of participants. This is particularly important for topics like fatigue, cognition, and immunity, where the placebo effect, individual variations, and sleep or diet quality can significantly influence the results.
The overall message emerging from the 2024-2026 data is fairly consistent. The "immunity" axis appears most credible for reishi and cordyceps, while the "cognition" axis is primarily explored for lion's mane. However, for clinical fatigue and lasting cognitive benefits, the evidence remains too limited to speak with certainty.
Reishi and immunity: real biological signals, but promises to be tempered
In the field of immunity, reishi is probably the best documented of the three mushrooms mentioned here. A randomized, double-blind, placebo-controlled trial included 60 volunteers initially, with 39 participants in the final analysis, all elderly women. Ganoderma lucidum was associated with modulation of T-cell function, suggesting an effect on adaptive immunity.
Another randomized, double-blind, placebo-controlled trial evaluated a β-1,3;1,6 D-glucan derived from reishi in healthy adults aged 18 to 55. The aim was to examine immunomodulation and safety. This type of work is valuable because it focuses on specific immune markers and a healthy population, which helps to determine whether the observed effect represents a true physiological signal.
That said, we must avoid jumping to conclusions. A GRADE meta-analysis published in 2025, combining 17 randomized controlled trials with 971 participants, did not demonstrate robust effects on major clinical immune endpoints. Effects were observed on some metabolic markers, but no significant benefit was found on several inflammatory markers. In practical terms, this means that reishi appears capable of influencing certain immune parameters, without this yet clearly translating into a major, proven clinical benefit.
Reishi and fatigue: encouraging results, but few convincing modern studies
When it comes to fatigue, the case for reishi becomes more tenuous. A large cross-sectional study of 1,374 cancer patients reported that 52% of participants felt their fatigue had improved “quite a bit or very much” after using reishi. This is an interesting finding, as it reflects the real-life experience of a large number of people.
The problem is that these are self-assessments, not a randomized controlled trial. Therefore, we cannot know for certain what proportion of the perceived improvement is due to reishi itself, other treatments, a waiting effect, or a natural progression of the overall condition. In other words, this type of data is useful for generating hypotheses, but not for proving efficacy.
There is also an older trial in patients with Gulf War Illness, in which Ganoderma lucidum was tested for symptom severity, pain, and fatigue in a placebo-controlled crossover design. However, this data is old, limited, and not currently considered a reliable recent reference. Therefore, if your primary goal is fatigue, the literature on reishi remains suggestive but not clinically sound.
Cordyceps and immunity: a promising field that is beginning to take shape
Cordyceps, particularly Cordyceps militaris, is attracting considerable interest for its immunomodulatory potential. A 2024 randomized trial, published in Scientific Reports, evaluated a cordyceps-based beverage in healthy adults. This is one of the most relevant recent human trials on this topic, as it directly targets the immune response in a well-defined population.
This type of study is important because it finally connects marketing claims with concrete human data. The results don't automatically mean that cordyceps "boosts" immunity in a broad sense, but they do reinforce the idea that it can modulate certain immune responses. In simpler terms, this is more about regulation or biological influence than a universal immune superfuel.
A 2025 review supports this view, concluding that Cordyceps militaris as an immunomodulatory, antitumor, and neuroprotective agent, while emphasizing that human evidence remains limited. This is a key point for understanding new developments: the mechanisms are compelling, the initial trials are encouraging, but large, replicated studies are still lacking to confirm the true extent of the benefits.
Cordyceps, fatigue and performance: more endurance studied than clinical fatigue
Cordyceps is often presented as an energy booster. However, recent human literature primarily focuses on performance, oxygenation, and recovery, rather than clinical fatigue in the medical or everyday sense. A 2025 review on the ergogenic benefits of Cordyceps emphasizes the need for further human studies, including at the cellular level.
In practical terms, this means that if you're looking for potential support for endurance or exertion, cordyceps offers a more active research angle. However, if you want to know whether it actually reduces a feeling of persistent fatigue, current trials don't yet provide a clear answer. The two concepts are similar in everyday language, but they are not scientifically equivalent.
It is therefore best not to confuse improvement in certain exercise-related parameters with a proven reduction in chronic or functional fatigue. Cordyceps remains a promising avenue, but the most robust data to date do not yet directly address clinical fatigue.
Cordyceps and cognition: an interesting acute signal, but without lasting evidence at present
Cordyceps is also beginning to show some signs of cognitive improvement, but these remain preliminary. A very recent randomized crossover trial of acute supplementation observed faster reaction times, along with an increase in resting oxygen consumption. This is an intriguing result, as it suggests a measurable functional effect in the short term.
That said, it's important to interpret what the study actually says. An acute improvement in reaction times doesn't necessarily mean lasting cognitive improvement, nor does it guarantee an effect on memory, sustained attention, or executive functions over several weeks. This is a rapid signal, potentially useful for guiding future trials, but not a definitive proof.
For the moment, cordyceps is therefore more credible in terms of physiological and performance parameters than in terms of a strong promise as a confirmed "nootropic." If new, long-term studies replicate these results, the picture could change, but this is not yet the case.
Lion's mane and cognition: much interest, still few certainties
Lion's mane, or Hericium erinaceus, is the mushroom most often associated with cognition. A randomized, double-blind, placebo-controlled trial published in 2025 in healthy young adults tested a standardized extract. The conclusion was cautious: further research is needed to confirm a long-term benefit on cognition and mood.
This caution is consistent with recent reviews. A clinical review notes that a very small trial in people with mild cognitive impairment showed temporary improvement, but that this result has not yet been convincingly replicated. In science, the lack of robust replication severely limits the practical application of an initial result, however encouraging it may be.
In other words, lion's mane remains a serious candidate for cognitive research, but not yet a robustly validated solution. There is genuine scientific interest, some positive signals, and plausible mechanisms, but the human clinical basis remains modest.
Lion's mane, mood, security, and overall level of evidence
Beyond pure cognition, the lion's mane is also being explored in relation to mood. Here again, trials remain few and often small. The 2025 systematic review identified 5 randomized controlled trials, 3 pilot trials, and other studies with a lower level of evidence. This shows that human data do exist, but that they remain insufficient to draw firm and generalizable conclusions.
Regarding safety, recent reviews highlight a generally well-studied profile, but not enough to conclude that there is broad clinical efficacy. This is an important distinction. A product may show an acceptable safety profile in available studies without this automatically confirming a net benefit on memory, concentration, or emotional well-being.
For discerning consumers, the best approach is to distinguish between three levels: observed safety, potential efficacy signals, and robust clinical evidence. In the case of lion's mane, the first level is progressing, the second exists, but the third is still under development.
How can we interpret these results without falling into hype marketing?
A summary of recent clinical trials on reishi, cordyceps, and lion's manereveals a fairly clear hierarchy. Reishi and cordyceps show the most credible signals regarding immunity, while lion's mane is the focus of most research on cognition. In contrast, the evidence on fatigue remains weaker and often indirect, especially when seeking a clear clinical improvement.
To interpret these results effectively, one must also consider the form used: standardized extract, functional beverage, isolated beta-glucans, dosage, duration, participant profile, and measured criteria. Two products bearing the same mushroom name can actually have very different compositions and potential effects. This is precisely why laboratory data, transparency, and compliance are so important in the world of natural wellness.
Finally, let's maintain a balanced perspective. These mushrooms are neither gimmicks nor miracle cures. They belong to a category of promising ingredients, with real but still incomplete human-like signals. For adults who like to explore wellness solutions seriously, the best mindset is simple: curiosity, patience, and attention to quality rather than blind adherence to slogans.
In conclusion, the new clinical trials on reishi, cordyceps, and lion's mane paint a more credible, but still incomplete, picture than before. Reishi appears capable of modulating certain immune parameters, cordyceps shows interesting potential for immunity and some functional indicators, while lion's mane remains the most studied candidate for cognitive function. However, in all three cases, human evidence is not yet sufficient to establish broad, consistent, and universal benefits.
The best approach for making informed choices is to prioritize transparent, tested, and well-formulated products, while maintaining realistic expectations. If you're interested in these active ingredients to complement a wellness routine, the most reliable approach remains the same: examine the data, verify the quality, and favor measured claims over hype that seems too good to be true.
